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S308 Poster Session Iof using donors that are not fully matched on both GVHD incidence
and overall survival. Historically there is evidence that an isolated C
mismatch may not affect these outcomes but this has been evaluated
almost exclusively in adult patients with hematologic malignancies.
We collected data on a 146 consecutive pediatric patients (median
age 9 years) who received an unrelated donor transplant at Children’s
Hospital Boston from 1/2004 through 12/2010 for malignant and
nonmalignant conditions. 97% received bone marrow as the stem
cell source and 97% received fully myeloablative conditioning.
75% underwent HSCT for a hematologic malignancy (leukemia/
lymphoma), 11% for immunodeficiency and the remainder for other
indications, primarily bone marrow failure syndromes. 70% of pa-
tients had a donor fully matched at both A,B,C,DR, DQ loci on
high resolution typing, 10% had a single C mismatch and the re-
maining 20% had a donor with 1 or 2 other mismatches excluding
a single C mismatch (none had a DR mismatch and all were at least
a 5/6 match on A, B, DR). 45% experienced GVHD: 13% acute
only, 51% chronic only and 32%both. There was no statistically sig-
nificant difference in the proportion of patients who had acute
GVHD of any grade and/or limited or extensive chronic GVHD be-
tween those having a fully matched, single C mismatch or other mis-
matched donor (p5 0.7). There was also no significant difference in
survival between the groups. 100 day and 1 year overall survival were
93%/77% with fully matched donors, 87%/60% for single C mis-
matched donors (p 5 0.2) and 96%/76% for other mismatched do-
nors. Thus it appears that in the era of high-resolution HLA typing
and improved supportive care HLA mismatched donors can provide
outcomes similar to those using fully matched donors in pediatric
patients undergoing HSCT for malignant and nonmalignant
conditions.Table 1. Association between AUC-all and AUC generated
by LSSs
Sample times
(hours after start of
infusion) Adjusted r2
Mean bias
(%; range) Precision (%)
2, 3 and 4 0.9962 0.05 (-5.3 to 4.6) 3.6
2, 3, 4 and 10 0.9981 0.03 (-2.0 to 2.0) 1.2
2, 2.5, 3, 4 and 10 0.9990 0.05 (-2.0 to 3.0) 0.9278
EPIDEMIOLOGY OF BACTERIAL, FUNGAL AND VIRAL INFECTIONS IN
CHILDREN AND ADOLESCENTS AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Srinivasan, A.1, Wang, C.2, Srivastava, D.K.2, Leung, W.H.1,
Hayden, R.T.3 1St.Jude Children’s Research Hospital, Memphis, TN;
2St.Jude Children’s Research Hospital, Memphis, TN; 3St.Jude Child-
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The epidemiology of bacterial, fungal and viral infections was
retrospectively analyzed in a cohort of 759 children and adolescents
who underwent allogeneic hematopoietic stem cell transplantation
(HSCT) in a single institution, between 1990-2009, to study the
impact of changes in transplantation methodology on the distribu-
tion of pathogens and mortality due to infections. There were 243
matched-related, 239 matched-unrelated (MUD) and 176 haplo-
identical donor transplants. Independent logistic regression was
conducted at 0-30 days (A), 30-100 days (B) and .100 days (C)
post-transplant. On multivariate analysis, total body irradiation (p
5 0.001, A; 0.005, C), apheresis product (p 5 0.02, A; 0.01, B),
acute (p 5 0.002, B) and chronic (p 5 0.03, C) graft vs host disease
(GVHD) were associated with higher risk for bacterial infections at
the respective time periods. CMV serostatus (p 5 0.05, B), pres-
ence of acute (p 5 0.001, B), chronic GVHD (p\0.001, C) and
age .10 yrs (p 5 0.02, C) were associated with higher risk for fun-
gal infections. CMV serostatus (p 5 0.0005, A; 0.03 B; 0.002 C),
acute (p 5 0.01, A) and chronic GVHD (p 5 0.001, C), were asso-
ciated with higher risk for viral infections. MUD donor transplants
were associated with a higher risk of viral infections (p 5 0.001).
Bacterial (p 5 0.002) and fungal (p 5 0.0004) infections in period
A, decreased in the 2005-2009 era. There were 321 episodes of bac-
teremia in 231(30%) patients, of whom 168 episodes (52%) were in
period C. Staphylococcus epidermidis (33%) and Escherichia coli (12%)
were the most common causes of bacteremia. Candidemia, mostly
C.albicans, was detected in 49 (6%) patients, 26 (54%) in period C.
There were 45 patients with proven aspergillosis, 20 (44%) in pe-
riod A. Non-aspergillus molds were detected in 16 (2%) patients.
CMV and adenoviremia was detected in 146 (20%) and 68 (9%)
patients respectively. Parainfluenza was the most common respira-
tory viral infection detected in 70 (9%) patients, 35(50%) in period
C. This is the largest retrospective study providing a time line of
infections in children and adolescents who have undergone alloge-
neic HSCT.279
CYCLOSPORINE AREA UNDER THE CURVE IN CHILDREN UNDERGOING
HAEMATOPOIETIC STEM CELL TRANSPLANTATION: LIMITED SAMPLING
STRATEGY AT STEADY-STATE
Schechter, T.1, Teuffel, O.1, Gibson, P.2, Sung, L.1, Seto,W.3, Gassas, A.1,
Doyle, J.1, Dupuis, L.L.1 1The Hospital for Sick Children, Toronto, ON,
Canada; 2London Health Sciences Centre, London, ON, Canada; 3The
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Haematopoietic stem cell transplantation (HSCT) outcomes may
be optimized by cyclosporine dose adjustment according to systemic
exposure (measured by area under the curve (AUC)) rather than
trough concentration. We have previously developed and validated
a limited sampling strategy (LSS) for estimating cyclosporine AUC
after the initial IV dose in children undergoing HSCT. In this study
we aim to develop a LSS to estimate AUC at steady-state.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12h as a 2-hour infusion and methotrexate/methylprednisolone
for acute graft-versus-host disease (GVHD) prophylaxis were eligi-
ble. Cyclosporine AUC was determined once weekly until engraft-
ment using 9 concentration-time points. Steady state was defined
as being reached after administration of 4 identical doses.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
values . 0.9 were acceptable. Precision and mean bias \ 15%
were acceptable.
18 children (0.3-17 years) participated. Mean actual dose infu-
sion time was 1236 4.4 min. Mean AUC-all at steady state was
489461386 h*mcg/L. Individual cyclosporine whole blood concen-
trations drawn at 2, 2.5, 3, and 4 hours after the start of the infusion
correlated most highly with AUC-all (Spearman rho coefficient:
0.847, 0.926, 0.942, and 0.903, p\0.0001, respectively). Values of
AUC predicted by the 3, 4 and 5-point LSS were strongly associ-
ated with AUC-all (spearman rho coefficient . 0.998;
p\0.0001).The 3-point LSS (2, 3 and 4 hours) is likely the method
of choice for determining cyclosporine AUC at steady state when
given as 2 hour infusion to children undergoing HSCT. Validation
of the LSS in a different sample is required before this LSS strategy
can be implemented. The relationship between acute GVHD and
cyclosporine AUC at different time periods after HSCT merits
further study.280
THROUGH THEIR EYES: THE EXPERIENCES OF THE MINOR AND YOUNG
ADULT MATCHED SIBLING HEMATOPOIETIC CELL DONORS – A RETRO-
SPECTIVE STUDY FROM A SINGLE REGIONAL INSTITUTION
Kasow, K.A.1, D’Auria, J.2, Presler, C.1, Fitzgerald, T.1, Sharf, S.E.‘‘S.’’3
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Univer-
sity of North Carolina at Chapel Hill, Chapel Hill, NC; 3University of
North Carolina at Chapel Hill, Chapel Hill, NC
Matched sibling donor hematopoietic cell transplantation (HCT)
is considered the standard of care for many disorders, yet the donor’s
emotional and physical needs may be overlooked and the donor
viewed as a therapeutic modality in the process of saving the life of
an ill sibling. In this IRB-approved study, we explored the meaning
of the donor’s experiences through his own words and recollections,
and the contextual influences and critical events across the transplant
trajectory. A semi-structured interview was conducted in private
Poster Session I S309with each of the eight participants. The participants were minor/
young adults who served as a donor for a successful HCT between
January 1999-September 2009. Median donor age at time of HCT
was 13 years (yrs) (range, 2-23 yrs) and the interview 18.5 yrs (range,
13-30 yrs). Median time between donation and interview was 6.5 yrs
(range, 2-10 yrs). Interviews were audio-taped, transcribed, verified,
and de-identified. A grounded theory approach was used to analyze
interview data in aggregate. The sibling world exerts a powerful in-
fluence on shaping the social experiences and problems children will
face across time and development. The transplant experience inten-
sified the sibling donor-recipient bond. Saving my sibling’s life de-
scribed the central phenomenon that captured the memories of
these donors. The life-saving bond reflected the donors’ desires to
help their sibling and keep them in their lives. Five themes unfolded:
a) being the perfect match; b) stepping up; c) worrying about the out-
come; d) the waiting process; and e) sharing a special bond. The first
memory of the donation process centered on beingHLA tested. Par-
ticipants insisted there was no decision about stepping up to be the
donor. They felt immense pressure to be that perfect match to
save their sibling and worried about being the reason their sibling
might die. Participants recalled expecting the donated bone marrow
to take immediate affect, not realizing it takes time for new bone
marrow to function normally. Findings provided new insights into
the complexities of sibling relationships when one has a potentially
life-threatening illness. Interventions targeting this relationship
must be congruent with the cognitive skills and social experiences
of the donor. The quality of the relationship is a critical contextual
factor that provides an entry point for positively impacting adapta-
tion to the donation process and future coping with stressful
situations.281
STEM CELL TRANSPLANT (HSCT) IN PEDIATRIC CML: IS TRANSPLANTA-
TION THE STANDARD OF CARE? THE CHILDREN’S MEMORIAL HOSPITAL
(CMH) EXPERIENCE
Chaudhury, S.1, Broglie, L.1, Tse, W.1, Duerst, R.1, Schneiderman, J.1,
Rademaker, A.2, Kletzel, M.1, Hijiya, N.1 1Childrens Memorial Hospital,
Northwestern University Feinberg School of Medicine, Chicago, IL;
2Northwestern University Feinberg School of Medicine, Chicago, IL
Introduction: Chronic Myeloid Leukemia (CML) in pediatrics is
rare. Allogeneic hematopoietic stem cell transplantation (HSCT) is
considered curative treatment for CML. Tyrosine kinase inhibitors
(TKI) are increasingly used as a safe alternative that provide pro-
longed disease control.
Methods:We performed a review of pediatric patients with CML
who received allogeneic HSCT at CMH, Chicago, from
1992-2011.
Results:There were 21 consecutive patients with CML in chronic
phase at the time of HSCT. Mean age at HSCT was 9.6 y (range
0.3 -18 y) and mean time to HSCT from diagnosis was 9.5 m
(range 4-36 m). Eleven (52%) patients did not receive a TKI prior
to HSCT (before 1999). Donors were HLA matched related do-
nors in 9 (43%), HLA matched unrelated donors in 9 (43 %),
and HLA mismatched related donors in 3 (14%). HSC source
was peripheral blood in 9 patients (43%), cord blood in 2 (9.5%),
and bone marrow in 10(47.5%). Fifteen of 21 (71%) patients re-
ceived a myeloablative (MA) conditioning regimen while reduced
intensity conditioning (RIC) regimens were used for 6 (29 %). Me-
dian follow up time post HSCT was 6 y (range 2-17 y). One year
event free survival (EFS) and overall survival (OS) were 60% and
75%, respectively and five-year EFS and OS were 49% and 59%
respectively. All but 2 patients engrafted. Three relapsed (bcr:abl
+), and 8 died secondary to complications. One relapsed patient
and 1 patient with graft failure received a second HSCT. Two re-
lapsed patients went into remission with TKI treatment. Two pa-
tients unsuccesfully received additional donor lymphocyte
infusions for graft failure. Acute ($ grade II) and chronic graft-
versus-host disease (GVHD) was seen in 15 (71%) and 5 (24 %) pa-
tients, respectively. Causes of death included graft failure (n 5 1);
aGVHD (n 5 2); sinusoidal obstruction syndrome (n 5 2); exten-
sive cGVHD (n 5 2) and post transplant lymphoproliferative
disease (n 5 1). On univariate analysis, there was no correlationof outcome with WBC count at diagnosis, time to HSCT, bcr:abl
+ at HSCT, conditioning regimen, prior TKI use, CMV serostatus,
donor type and HLA match, or cell dose.
Conclusions: We conclude that HSCT remains a curative option
for pediatric CML as evidenced by an OS of 59% at 5 years. In
our cohort of CML patients transplant-related mortality and not re-
lapse was the major cause of death. Larger series of patients are
needed to establish a cohort that would benefit fromHSCT upfront
incorporating less toxic conditioning regimens.
Table. Outcomes post HSCT in pediatric CML
Outcome Total N 5 21 MA N 5 15 RIC N 5 6Graft Failure 2 1 1
Acute GVHD 15 10 5
Chronic GVHD 5 2 3
Relapse(bcr:abl +) 3 1 2
Received 2nd Transplant 2 1 1
Mortality + 8 6 2
Mortality 2 13 9 4 (2 alive on TKI)282
EVALUATION OF THE UTILITY OF PRE-HSCT BRAIN MRIS IN PEDIATRIC
PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Bailey-Olson, M.F.1, Owens, A.1, Horn, B.N.1, Cowan, M.J.1,
Dvorak, C.C.1, Mueller, S.2 1UCSF Benioff Children’s Hospital, San
Francisco, CA; 2UCSF Benioff Children’s Hospital, San Francisco, CA
Introduction: Adverse neurological events and new neurological
symptoms (NS) are frequent complications of pediatric hematopoi-
etic stem cell transplant (HSCT). UCSF Benioff Children’s Hospi-
tal routinely obtains pre-HSCT brain MRI in pediatric patients
with hematologic malignancies undergoing HSCT. However the
utility of this standard practice is not well-known. The purpose
of this study is to evaluate risk factors for abnormal pre-HSCT
brain MRI and if surveillance brain MRIs prior to HSCT can pre-
dict NS in post-HSCT period in pediatric patients with hemato-
logic malignancies.
Patients & Methods: Retrospective chart analysis was done in 121
children with a hematological malignancy receiving HSCT (0-22
years) between 2000 and 2009 at UCSF. Nineteen patients were ex-
cluded because they did not undergo pre-HSCT brain MRI or
results were not recorded. Charts were reviewed forNS up to 2-years
post-HSCT. NS included both acute symptoms that resolved and
chronic conditions. A pediatric neurologist reviewed all abnormal
brain MRI reports. Descriptive statistics and two-tailed Fisher’s Ex-
act test were used to analyze the data.
Results:Of the 102 patients included in analysis, 46 patients (45%)
had abnormal brain MRI pre-HSCT. Most common MRI abnor-
malities were white matter changes (n 5 21) and volume loss (n
5 12). The only significant risk factor for abnormal brain MRI
was pre-HSCT neurological symptoms (p\0.001). Multiple risk
factors were not significantly associated with abnormal MRI in-
cluding disease type and presence of pre-HSCT neuropsychologi-
cal symptoms, CNS disease, intrathecal chemotherapy or cranial
radiation. A total of 19 patients (19%) developed new NS during
or post-HSCT. The only significant risk factor for new NS was
conditioning regimen including total body irradiation (TBI) as op-
posed to myeloblative chemotherapy (p 5 0.006). Presence of ab-
normal pre-HSCT MRI was overall not predictive of new NS
during and post-HSCT.
Conclusion: Although many pediatric patients with hematological
malignancies undergoing HSCT have abnormal findings on pre-
HSCT brain MRI, these patients do not have higher likelihood of
developing new neurological symptoms during and post-HSCT.
Surveillance brain MRI pre-HSCT may be useful in patients with
pre-HSCT neurological symptoms to document baseline abnormal-
ities however routine screening of all patients may not be clinically
warranted as a method of predicting neurological sequelae during
and post-HSCT.
